KDC-MN-309 – Kodiac biolabs

Plain-language summaryIntrigue 42 / 100

Cinnarizine is a 1970s Janssen compound that hits multiple targets at once: T-type calcium channels (cerebrovascular dilation, vestibular nerve effects), H1 histamine receptors (antihistamine), and weakly D2 dopamine receptors. The combined activity makes it useful for vertigo, motion sickness, and cerebrovascular insufficiency. Approved across Europe and Asia, never in the US. The D2 antagonism produces a small but real risk of drug-induced parkinsonism with long-term use, especially in elderly patients, which has limited enthusiasm. The motion sickness use is well-established. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

41/100

A 1970s multi-target CCB/antihistamine with narrow vestibular probe value but little frontier appeal

Look, cinnarizine is a 1970s Janssen compound that does several things reasonably well and none of them in a way thats particularly exciting to a researcher in 2026. T-type voltage-gated calcium channel inhibition, H1 antihistamine activity, and weak D2 dopamine receptor antagonism: that’s a multi-target profile, which sounds interesting until you realize all three arms of it are thoroughly mapped territory. There is no live mechanism question here.

The T-type CCB angle is the most research-interesting piece. T-type channels have gotten real attention in chronic pain, absence epilepsy, and cardiovascular biology, and cinnarizine functioned as a workable probe before more selective tools like Z944 or NCC-55-0396 came along. But “was useful before better tools existed” isn’t the same as “is useful now.” For anyone doing serious T-type channel work in 2026, cinnarizine’s selectivity profile is a liability. You’re blocking H1 and touching D2 whether you want to or not, which means you’re not probing T-type channels; you’re running a three-target pharmacology experiment with only partial control over two of the targets.

The vestibular pharmacology angle is where cinnarizine holds its remaining bench value. It’s a reference compound in that space, and if your program touches labyrinthine calcium dynamics or vestibular compensation, its approved clinical status in Europe gives you a reasonable phenotype-to-compound anchor. The evidence base is real: multi-decade literature, regulatory approval in EU and Asia, clear clinical signal in vertigo and motion sickness populations. That said, the original approval trials are not by modern methodological standards, and the cerebrovascular insufficiency indication sits on softer ground than the vestibular work.

The D2 antagonism is genuinely problematic from a research design perspective. It’s not an asset; it’s a confounder. Any experiment where dopaminergic tone matters gets complicated by the fact that you’re running a mild D2 blocker alongside whatever else you’re studying. In aged animal models especially, the extrapyramidal liability is a real concern that limits translational utility. Its US non-approval is sometimes cited as intrigue, but honestly it reflects nothing more than a risk calculus applied to a compound that doesn’t offer anything a US investigator can’t get from more selective tools.

We don’t think cinnarizine is junk. For narrow vestibular or inner-ear calcium dynamics studies, it retains genuine reference value, and the multi-target profile produces interpretable pharmacology when you specifically want simultaneous vascular and histamine pathway modulation. But this is a 50-year-old drug whose mechanism is fully characterized, whose indications are well-served by existing data, and whose research frontier was crossed a long time ago. A bench scientist centering a 2026 program on cinnarizine is probably reconstructing history rather than generating it.

Novelty: 22
Mechanism promise: 38
In-category differentiation: 38
Evidence quality: 52
Translational signal: 58
Research bench value: 44

Rationale Cinnarizine is a fully characterized 1970s Janssen compound whose T-type CCB/H1/weak-D2 profile is thoroughly mapped; bench value is real but narrow (vestibular pharmacology reference use), novelty is minimal, and the D2 confounder limits clean experimental design in most modern research programs.

Diphenylmethyl-piperazine calcium channel blocker / antihistamine

A diphenylmethyl-piperazine T-type calcium channel blocker with antihistamine activity; used for vertigo, motion sickness, and cerebrovascular disease.

Abstract

Cinnarizine (1-(diphenylmethyl)-4-(3-phenyl-2-propenyl)piperazine; CAS 298-57-7; molecular formula C26H28N2; molecular weight 368.52) is a diphenylmethyl-piperazine multi-target compound developed at Janssen and approved in many European and Asian markets in the 1970s. Mechanism: T-type voltage-gated calcium channel inhibition (cerebrovascular dilation, vestibular nerve effects), H1 antihistamine activity, and weak D2 dopamine receptor antagonism. The combined activity supports use in vestibular disorders, motion sickness, and cerebrovascular insufficiency. The D2 antagonism produces a small but real risk of extrapyramidal side effects (parkinsonism, tardive dyskinesia) with long-term use, particularly in elderly patients; this has limited use in some jurisdictions. Plasma half-life is approximately 4 hours. Approved for vertigo, motion sickness, and cerebrovascular disease in EU and Asia; not approved in the US. Used as a multi-target reference compound for vestibular pharmacology.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-309Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Tag: KDC-MN-309

Cinnarizine

Abstract

Read the full monograph